kwic
further
further
right
off
ON
198
1
100
500
strict
ELIZA cgi-bash version rev. 1.91
- Medical English LInking keywords finder for the PubMed Zipped Archive (ELIZA) -
return
kwic search for further out of >500 occurrences
298283 occurrences (No.79 in the rank) during 5 years in the PubMed. [cache]
--- ABSTRACT ---
--- ABSTRACT END ---
[frequency of next (right) word to further]
298283 occurrences (No.79 in the rank) during 5 years in the PubMed. [cache]
| 198) These findings support the further evaluation of eIF4F-targeted molecules in combination therapies with TKIs in B-ALL and other blood cancers. |
| PMID:34737376 DOI:10.1038/s41598-021-00950-y |
| 2021 Scientific reports |
| * Targeting eIF4F translation complex sensitizes B-ALL cells to tyrosine kinase inhibition. |
| - The mechanistic target of rapamycin (mTOR) is a kinase whose activation is associated with poor prognosis in pre-B cell acute lymphoblastic leukemia (B-ALL). These and other findings have prompted diverse strategies for targeting mTOR signaling in B-ALL and other B-cell malignancies. In cellular models of Philadelphia Chromosome-positive (Ph+) B-ALL, mTOR kinase inhibitors (TOR-KIs) that inhibit both mTOR-complex-1 (mTORC1) and mTOR-complex-2 (mTORC2) enhance the cytotoxicity of tyrosine kinase inhibitors (TKIs) such as dasatinib. However, TOR-KIs have not shown substantial efficacy at tolerated doses in blood cancer clinical trials. Selective inhibition of mTORC1 or downstream effectors provides alternative strategies that may improve selectivity towards leukemia cells. Of particular interest is the eukaryotic initiation factor 4F (eIF4F) complex that mediates cap-dependent translation. Here we use novel chemical and genetic approaches to show that selective targeting of either mTORC1 kinase activity or components of the eIF4F complex sensitizes murine BCR-ABL-dependent pre-B leukemia cells to dasatinib. SBI-756, a small molecule inhibitor of eIF4F assembly, sensitizes human Ph+ and Ph-like B-ALL cells to dasatinib cytotoxicity without affecting survival of T lymphocytes or natural killer cells. These findings support the further evaluation of eIF4F-targeted molecules in combination therapies with TKIs in B-ALL and other blood cancers. |
[
right
kwic]
(1)83  research |
(16)4 validation |
(31)2 and |
(46)2 high-quality |
| (2)43 studies |
(17)3 confirmed |
(32)2 attention |
(47)2 inform |
| (3)22 investigation |
(18)3 demonstrate |
(33)2 characterization |
(48)2 insight |
| (4)9 analysis |
(19)3 demonstrated |
(34)2 clinical |
(49)2 reduce |
| (5)9 study |
(20)3 highlight |
(35)2 considerations |
(50)2 research, |
| (6)7 the |
(21)3 identify |
(36)2 develop |
(51)2 screening |
| (7)7 work |
(22)3 in |
(37)2 developing |
(52)2 showed |
| (8)5 development |
(23)3 investigated |
(38)2 discussion |
(53)2 structure-based |
| (9)5 evidence |
(24)3 investigations |
(39)2 divided |
(54)2 studied |
| (10)4 evaluate |
(25)3 literature |
(40)2 enhanced |
(55)2 supported |
| (11)4 evaluation |
(26)3 our |
(41)2 evaluated |
(56)2 tested |
| (12)4 exploration |
(27)3 show |
(42)2 evaluations |
(57)2 this |
| (13)4 explore |
(28)3 we |
(43)2 examined |
(58)2 understand |
| (14)4 improve |
(29)2 aid |
(44)2 explored |
(59)2 understanding |
| (15)4 investigate |
(30)2 analyses |
(45)2 extend |
add keyword
--- WordNet output for further ---